Validating METCAM/MUC18 as a Novel Biomarker to Predict the Malignant Potential of Prostate Cancer at an Early Stage by Using a Modified Gold Nanoparticles-Based Lateral Flow Immunoassay

(1) Background: To further validate METCAM/MUC18 as a diagnostic biomarker for prostate cancer, a modified Lateral Flow Immune Assay (LFIA) with increased sensitivity and specificity was designed by taking advantage of the extremely high affinity between biotin and streptavidin and used. (2) Methods...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jui-Chuang, Chuang, Yin-Huan, Wei, Yu-Chun, Hsieh, Chia-Chi, Pong, Yuan-Hung, Su, Yenn-Rong, Tsai, Vincent F.-S., Wu, Guang-Jer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000444/
https://www.ncbi.nlm.nih.gov/pubmed/33806580
http://dx.doi.org/10.3390/diagnostics11030443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000444/
https://www.ncbi.nlm.nih.gov/pubmed/33806580
http://dx.doi.org/10.3390/diagnostics11030443

Ejemplares similares